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Conclusions: Many RO in Japan perceived a discrepancy between ideal and actual
treatments for BM. The promotion of multidisciplinary conferences may resolve this
discrepancy.
Legal entity responsible for the study: Ethical Guidelines for Medical Research.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background: In recent years, more head and neck cancer patients have been treated
with radiotherapy and chemotherapy. Radiation-induced mucositis, oral fibrosis,
burning mouth syndrome are common and dose limiting toxicity of radiotherapy as
well as chemotherapy among patients with head and neck cancers. A number of new
agents applied locally or systemically to prevent or treat radiationinduced oral compli-
cations have been investigated, but there is no widely accepted prophylactic or effective
treatment for them.
Methods: A total 80 patients were randomized in double blind study to either AV (40
patients) or placebo (40patients), at a dose 5mg in form of gel three times a day. A visual
Analog Scale and subjective symptoms were used for rating pain, oral fibrosis, intra oral
dryness, eating ability, oral discomfort. The patients were evaluated after 4 and 8 weeks.
Results: Data analysis study groups that had been given aloe vera, by anova showed
that there was a statistically significant difference(p< 0.05) in pain, eating ability, and
oral discomfort as graded by visual analogue scale.
Conclusions: Within the limitations of this study aloe vera is effective as a natural
healer and anti-oxidant agent for preservation of oral mucous membrane and reduces
oral complications. As a potential choice, Aloe vera gel for palliative patients under-
going head and neck cancer treatment prevent oral complications.
Legal entity responsible for the study: Dr Surendra Beniwal.
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Background: Cell-free and Concentrated Ascites Reinfusion Therapy (CART) is
expected to improve some symptoms related to ascites. However, its efficacy and safety
for malignant ascites of pancreatic cancer (PC) patients has not been fully elucidated.
The aim of this study is to assess the clinical significance of CART in PC with malignant
ascites.
Methods: In this retrospective analysis, we examined 226 CART processes performed
on 54 patients with advanced PC from April 2010 to March 2018 in our institution.
Adverse events (AE) related to CART and patient’s symptoms were assessed by using
CTCAE v4.0. Improvements in ECOG Performance Status (PS) and patient’s symp-
toms were analyzed using Wilcoxon signed rank test. Survival analyses were performed
with Kaplan-Meier method, Log-rank test, and Cox-proportional hazard model.
Results: Patients characteristics were as follows: male/female 32/22, median age 70
(range 41-80), median number of CART 2 (range 1-42), PS (1/2/3/4) 10/22/18/4, pri-
mary surgery (Yes/No) 3/51, chemotherapy before CART (Yes/No) 35/19, and chemo-
therapy after CART (Yes/No) 16/38, respectively. Following initial CART, PS
(p¼ 0.003), anorexia (p< 0.001), and fatigue (p< 0.001) were significantly improved.
Three patients with PS3 and two patients with grade3 anorexia could receive chemo-
therapy along with improvement of their symptom after CART. The median overall
survival (OS) was 33.0 days (95% CI; 21.9-44.0). In Cox multivariate analysis, PS had
an independent prognostic impact (hazard ratio: 0.354, 95%CI: 0.163-0.771,
p¼ 0.009). Especially for PS0-2 patients after CART (N¼ 37), receiving chemotherapy
was significantly related to better OS (hazard ratio: 0.393, 95%CI: 0.177-0.874,
p¼ 0.022). There were no severe AE related to CART and treatment-related death.
Conclusions: CART was performed safely and was useful to improve some symptoms
for PC patients with malignant ascites. Our results suggested CART could be lead to
administrate the chemotherapy and may contribute to the improvement of survival in
patients with PC.
Legal entity responsible for the study: Kushiro Rosai Hospital.
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Background: Study of mindfulness breathing exercise in dyspnea reduction of patients
with advanced lung cancer is lacking.
Methods: This is a parallel-group, nonblinded randomized controlled trial of mindful-
ness breathing exercise versus placebo (best medical care alone) in patients with
advanced lung cancer admitted to the respiratory unit and palliative unit of University
Malaya Medical Center from 1st August 2017 to 31st March 2018.
Results: A total of 34 patients were equally assigned to mindfulness breathing exercise
group and control group (Table). For patients receiving mindfulness breathing exer-
cise, 10 (58.8%) of them had reduction in modified Borg dyspnea scale (MBDS) score
at 5-minutes (OR, 9.33; 95% CI, 1.80–48.38; p¼ 0.005) and 20-minutes (OR, 2.86;
95% CI, 0.67–12.11; p¼ 0.149), compared to only 3 (17.6%) and 7 (41.1%) of them in
control arm at 5-minutes and 20-minutes, respectively. 5 patients (29.4%) on mindful-
ness breathing exercise achieved improvement in their SpO2 compare to only 2 patients
(11.8%) of control arm had that at 5-minutes (OR, 3.75; 95% CI, 0.61–23.35;
p¼ 0.209). 4 patients (23.5%) on mindfulness breathing exercise had SpO2 improve-
ment at 20-minutes, while none in control arm had SpO2 improvement at same time.
Similar number of patients had reduced respiratory rate after mindfulness breathing
exercise or at control for 5-minutes [9 (52.9%) versus 10 (58.8%), (OR, 1.05; 95% CI,
0.26–4.32; p¼ 0.946)]. At 20-minutes, similar number of patients on mindfulness
breathing exercise still had sustained reduction in respiratory rate while only 7 patients
(41.1%) in control arm had similar respiratory benefit (OR, 2.14; 95% CI, 0.52–8.81;
p¼ 0.288).
Table: 360P Ideal and actual treatments for case scenarios
Case 1 Ideal treatment Actual treatment
Orthopedic surgeons 78% 22% 0% 64% 30% 6%
Medical oncologists 63% 37% 0% 47% 47% 6%
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Conclusions: Mindfulness breathing exercise is effective in reducing dyspnea among
patients with advanced lung cancer.
Legal entity responsible for the study: Ethic Committee of University Malaya Medical
Center.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background: Randomized clinical trials describe the benefit of chemotherapy for
advanced and incurable cancer patients with selected patient and disease characteris-
tics. The overall survival benefits for the whole population with incurable cancer
patients in Australia, if evidence-based guidelines for chemotherapy were imple-
mented, are unknown. This study’s purpose was to estimate the overall population sur-
vival benefit of first-course palliative chemotherapy if guidelines were followed.
Methods: Decision trees with evidence-based indications for chemotherapy have been
previously defined. Each branch of the tree corresponds to a specific cohort who have,
or do not have, defined indication for palliative chemotherapy. Palliative chemother-
apy survival benefit was defined as the absolute incremental survival benefit of first-
course chemotherapy over no chemotherapy (best supportive care), or over palliative
chemotherapy for palliative indications. Multiple electronic citation databases were
systematically queried, including Medline and Cochrane library. In cases where there
were multiple sources of the same level of evidence, then hierarchical meta-analysis was
performed. The survival benefits of palliative chemotherapy were estimated for 1- and
5-year. Sensitivity analyses were performed to assess the robustness of our estimates.
Results: 36% of survival benefit was attributed to first-course palliative chemotherapy.
The 1-year survival benefit of the entire cancer population was mostly contributed by
palliative indications. The estimated 1-year and 5-year absolute population-based over-
all survival benefits of optimally-used first-course chemotherapy for advanced and
incurable cancer were 3.6% (95% Confidence Interval, CI, 3.4%-3.7%) and 1.0% (95%
CI, 0.9%-1.0%), respectively.
Conclusions: First-course chemotherapy prolongs life for advanced and incurable can-
cer patients at 1-year and 5-years. Chemotherapy provides a modest survival benefit
when it is used in accordance with guideline recommendations. It is important to
include other relevant quality of life-adjusted endpoints and patient-reported out-
comes in future studies in this group of palliative patients.
Legal entity responsible for the study: Collaboration for Cancer Outcomes Research
and Evaluation.
Funding: Has not received any funding.
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Background: Palliative care is an integrated part of cancer patient care. However, the
situation in palliative care in Uzbekistan is very critical. Morphine consumption of
0.08 mg per capita is a direct indication of painful deaths in this country.
Methods: We have created a questionnaire which evaluates the general health condi-
tion and health status of the patients. Simultaneously, we have created questionnaire
for doctors to evaluate the status of their knowledge in palliative care. 500 patients from
cancer centers, at different stages of disease, and 82 oncologists were surveyed. The sur-
vey for patients included physical pain status, psychological condition of the patient
and self-evaluation of quality of life. Survey of doctors included evaluation of patient’s
pain status, patient’s mood and knowledge of pain control.
Results: Patients were in pain throughout the whole course of disease. Patients in late
stages had suffered from pain more than patients in early stages. Physical pain after sur-
gery noted in all patients the mean pain status was 5.7. Mostly, NSAIDs in combination
with H1 blockers were used to cope with pain, paracetamol was used only in one
patient. Narcotic analgetics (nalbuphine, tramadol, promedole morphine) were used
mostly during surgery, rarely in patients with stage IV disease and in postoperative
period. Most of the patients noted emotional fatigue and depression. However, the pre-
dominant number of patients did not know their diagnosis and possible prognosis.
More than half of the doctors (47-57.3%) knew the principles of step by step analgesia.
But only a few (2-2.43%) used it in their day-to-day practice. The reasons for opiopho-
bia were unwillingness of filling in different forms as well as utilization of empty ampu-
las, fear of dependency and incorrect evaluation of patient’s pain status.
Conclusions: Creating 15 departments of palliative care and 4 hospices throughout the
country are implemented in NCCP. All above mentioned institutions will have mobile
palliative care units. Protocols of palliative care and adequate pain control, simplifying
the drug administration as well as development of education are being developed
according to international standards.
Legal entity responsible for the study: National Cancer Center of Uzbeksitan.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
366P Socioeconomic status and demographic assessment of advanced
cancer patients in palliative care department of a tertiary care centre:
Observational study
G. Kumar
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Background: Cancer diagnosis may jeopardize the way of life of individuals and may
result in a range of potential social problems. Detection and characterization of social
problems has been found to improve care of cancer patients and result in improved
quality of life.
Table: 363P Demographic and clinical characteristic of patients




Control (n¼ 17) p value
Age, year Mean (þ SD) Range 64.0þ 11.3 27 – 80 63.7þ 10.2 42 - 80 64.3þ 12.6 27 – 78 0.882
Gender, No. (%) Male Female 17 (50.0) 17 (50.0) 9 (52.9) 8 (47.1) 8 (47.1) 9 (52.9) 0.732
Ethic, No. (%) Malay Chinese Indian 10 (29.4) 22 (64.7) 2 (5.9) 3 (17.6) 13 (76.5) 1 (5.9) 7 (41.2) 9 (52.9) 1 (5.9) 0.312
Religion, No. (%) Islam Buddhist Christian Hindu 10 (29.4) 22 (64.7) 1 (2.9) 1 (2.9) 3 (17.6) 13 (76.5) 1 (5.9) 0 7 (41.2) 9 (52.9) 0 1 (5.9) 0.228
ECOG, No. (%) 0-1 2-4 9 (26.5) 25 (73.5) 3 (17.6) 14 (82.4) 6 (35.3) 11 (64.7) 0.244
Cancer stage, No. (%) IIIb IV 4 (11.8) 30 (88.2) 3 (17.6) 14 (82.4) 1 (5.9) 16 (94.1) 0.287
Cor-morbid, No. (%) No Yes 27 (79.4) 7 (20.6) 12 (70.6) 5 (29.4) 15 (88.2) 2 (11.8) 0.203
Opioid treatment, No. (%) No Yes 23 (67.6) 11 (32.4) 13 (76.5) 4 (23.5) 10 (58.8) 7 (41.2) 0.271
Oxygen supplement, No. (%) No Yes 20 (58.8) 14 (41.2) 9 (52.9) 8 (47.1) 11 (64.7) 6 (35.3) 0.486
At 0-minute, MBDS Mean (þ SD) Range SpO2 Mean (þ SD)
Range Respiratory rate Mean (þ SD) Range
3.8þ 1.5 3-8 97.7þ 1.9
92-100 30.0þ 11.3 20-48
3.8þ 1.5 3-8 97.1þ 2.0 92-100
29.1þ 5.9 20-40
3.8þ 1.5 3-8 98.2þ 1.8
95-100 30.8þ 8.0 20-48
0.909 0.109
0.484
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